Selected publications
-
Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): A multicentre, open-label, randomised, phase 3 trial.
The lancet oncology.
2017
Academic Article
GET IT
Times cited: 33 -
A multicenter assessment of the ability of preoperative computed tomography scan and CA-125 to predict gross residual disease at primary debulking for advanced epithelial ovarian cancer.
Gynecologic Oncology.
2017
Academic Article
GET IT
Times cited: 4 - Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of gynecologic oncology and American society of clinical oncology clinical practice guideline. Obstetrical and Gynecological Survey. 2016 Comment GET IT
-
Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline.
Journal of Clinical Oncology.
2016
Review
GET IT
Times cited: 58 -
Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline.
Gynecologic Oncology.
2016
Academic Article
GET IT
Times cited: 32 -
Randomized phase II evaluation of bevacizumab versus bevacizumab plus fosbretabulin in recurrent ovarian, tubal, or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study.
Journal of Clinical Oncology.
2016
Academic Article
GET IT
Times cited: 20 -
A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study.
Gynecologic Oncology.
2015
Academic Article
GET IT
Times cited: 91 -
PTEN loss is a context-dependent outcome determinant in obese and non-obese endometrioid endometrial cancer patients.
Molecular Oncology.
2015
Academic Article
GET IT
Times cited: 15 -
Summary of the 2014 MD Anderson International Meeting in Gynecologic Oncology: emerging therapies in gynecologic cancer.
Gynecologic Oncology.
2014
Article
GET IT
Times cited: 3 -
Is bilateral lymphadenectomy for midline squamous carcinoma of the vulva always necessary? An analysis from Gynecologic Oncology Group (GOG) 173.
Gynecologic Oncology.
2013
Academic Article
GET IT
Times cited: 31 -
Lymphatic mapping and sentinel lymph node biopsy in women with squamous cell carcinoma of the vulva: A gynecologic oncology group study.
Journal of Clinical Oncology.
2012
Academic Article
GET IT
Times cited: 115 -
Reclassification of serous ovarian carcinoma by a 2-tier system: A Gynecologic Oncology Group study.
Cancer.
2012
Academic Article
GET IT
Times cited: 72 -
Proceedings from the 9th International Conference on Ovarian Cancer.
Gynecologic Oncology.
2012
Article
GET IT
Times cited: 1 -
Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer.
The lancet oncology.
2011
Academic Article
GET IT
Times cited: 76 -
Clinical and biological impact of EphA2 overexpression and angiogenesis in endometrial cancer.
Cancer Biology and Therapy.
2010
Academic Article
GET IT
Times cited: 31 -
Current academic clinical trials in ovarian cancer: Gynecologic Cancer Intergroup and US National Cancer Institute Clinical Trials Planning Meeting, May 2009.
International Journal of Gynecological Cancer.
2010
Review
GET IT
Times cited: 6 -
Plasma cell-free DNA in ovarian cancer: An independent prognostic biomarker.
Cancer.
2010
Academic Article
GET IT
Times cited: 61 -
Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer.
Molecular Cancer Therapeutics.
2010
Academic Article
GET IT
Times cited: 36 -
Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma.
Cancer Biology and Therapy.
2009
Academic Article
GET IT
Times cited: 32 -
EphA2 overexpression is associated with lack of hormone receptor expression and poor outcome in endometrial cancer.
Cancer.
2009
Academic Article
GET IT
Times cited: 39 -
Functional significance of VEGFR-2 on ovarian cancer cells.
International Journal of Cancer.
2009
Academic Article
GET IT
Times cited: 75 -
Erythropoeisis-stimulating agents (ESAs) in cervix cancer: The "black box" paradox.
Cancer Biology and Therapy.
2009
Comment
Times cited: 1 -
Dicer, Drosha, and outcomes in patients with ovarian cancer.
New England Journal of Medicine.
2008
Academic Article
GET IT
Times cited: 493 -
Targeting Aurora kinase with MK-0457 inhibits ovarian cancer growth.
Clinical Cancer Research.
2008
Academic Article
GET IT
Times cited: 48 -
Clinical and biological significance of vascular endothelial growth factor in endometrial cancer.
Clinical Cancer Research.
2007
Academic Article
GET IT
Times cited: 122 -
Antitumor and antivascular effects of AVE8062 in ovarian carcinoma.
Cancer Research.
2007
Academic Article
GET IT
Times cited: 55 -
Dual targeting of endothelial cells and pericytes in antivascular therapy for ovarian carcinoma.
Clinical Cancer Research.
2007
Academic Article
GET IT
Times cited: 67 -
Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma.
Cancer Research.
2007
Academic Article
GET IT
Times cited: 130 -
Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer.
Cancer Research.
2007
Academic Article
GET IT
Times cited: 111 -
Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer.
Cancer Biology and Therapy.
2006
Academic Article
GET IT
Times cited: 75 -
Antiangiogenic and antitumor effects of Src inhibition in ovarian carcinoma.
Cancer Research.
2006
Academic Article
GET IT
Times cited: 62 -
Focal adhesion kinasetargeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy.
Clinical Cancer Research.
2006
Academic Article
GET IT
Times cited: 251 -
Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma.
Nature Medicine.
2006
Academic Article
GET IT
Times cited: 588